Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Daily Feeds
Calendars
Economic Indicators
Class Actions
Calculators
Education
About Us
Working with TipRanks
Follow Us
Arcus Biosciences (RCUS)
:RCUS
Holding RCUS?
Track your performance easily
Earnings Data
Report Date
Feb 19, 2025TBA Not Confirmed
Period Ending
2024 (Q4)Consensus EPS Forecast
-1.25Last Year’s EPS
-1.08Same Quarter Last Year
Strong Buy
Based on 8 Analysts Ratings
---
Earnings Call Summary
Earnings Call Date:Nov 08, 2018
|% Change Since: -10.81%
|Next Earnings Date:Aug 06, 2018
Earnings Call Sentiment|Positive
The earnings call presented strong data for key drug candidates, significant progress in clinical trials, and a stable financial position, although strategic uncertainties with collaborations and competitive challenges in the RCC market were noted.Company Guidance
During Arcus Biosciences' Q3 2024 earnings call, the management provided comprehensive guidance, focusing on several key metrics and strategic updates. The call highlighted the launch of the late-stage development program for the HIF-2 alpha inhibitor casdatifan, with promising data from the ARC-20 study showing a primary progression rate of 19% in the 100-mg cohort and a 34% overall response rate (ORR), with a 25% confirmed ORR. Furthermore, the median progression-free survival (PFS) had not been reached, surpassing the belzutifan benchmark of 5.6 months. The company plans to present additional data from ARC-20 throughout 2025, including more mature ORR and median PFS. For domvanalimab, the ARC-10 study demonstrated a hazard ratio below 0.65 for both PFS and OS, reflecting strong efficacy. Financially, Arcus ended the quarter with $1.1 billion in cash, with GAAP revenue of $48 million, and expects its cash runway to extend into mid-2027. The anticipated opt-in decision by Gilead for the casdatifan program, potentially late this year or early next year, and the ongoing partnership with AstraZeneca and Taiho, are expected to further enhance Arcus's robust pipeline.Promising Data for HIF-2 Alpha Inhibitor
The ARC-20 study showed a 34% ORR and 25% confirmed ORR in the 100-mg cohort, with significant potential for further improvement. The median PFS has not been reached, suggesting strong efficacy in heavily pretreated patients.
Dom-Zim Combination Shows Strong Results
ARC-10 data showed a hazard ratio below 0.65 for both PFS and OS, with a median OS not reached with dom-zim in first-line PD-L1 high non-small cell lung cancer, outperforming contemporary benchmarks.
Financial Position and Collaborations
Arcus Biosciences has $1.1 billion in cash and investments, with a runway into mid-2027, bolstered by collaboration payments from Gilead and Taiho.
Phase 3 Trials and Development Plans
Multiple Phase 3 trials, including PEAK-1 and STAR-221, are underway, targeting significant market opportunities across various cancer indications.
---
RCUS Earnings History
The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.
Beat
Missed
---
RCUS Earnings-Related Price Changes
Report Date | Price 1 Day Before | Price 1 Day After | Percentage Change |
|---|---|---|---|
| Nov 06, 2024 | $15.73 | $16.46 | +4.64% |
| Aug 08, 2024 | $13.69 | $15.61 | +14.02% |
| May 08, 2024 | $15.26 | $16.15 | +5.83% |
| Feb 21, 2024 | $16.41 | $19.67 | +19.87% |
Earnings announcements can affect a stock’s price. This table shows the stock's price the day before and the day after recent earnings reports, including the percentage change.
---
FAQ
When does Arcus Biosciences (RCUS) report earnings?
Arcus Biosciences (RCUS) is schdueled to report earning on Feb 19, 2025, TBA Not Confirmed.
What is Arcus Biosciences (RCUS) earnings time?
Arcus Biosciences (RCUS) earnings time is at Feb 19, 2025, TBA Not Confirmed.
Where can I see when companies are reporting earnings?
You can see which companies are reporting today on our designated earnings calendar.
What companies are reporting earnings today?
You can see a list of the companies which are reporting today on TipRanks earnings calendar.
What is RCUS EPS forecast?
RCUS EPS forecast for the fiscal quarter 2024 (Q4) is -1.25.
---